Rose Jonathan A, Tukpah Ann-Marcia C, Cutting Claire, Wada Noriaki, Nishino Mizuki, Moll Matthew, Kalra Sean, Choi Bina, Lynch David A, Raby Benjamin A, Rosas Ivan O, San José Estépar Raúl, Washko George R, Silverman Edwin K, Cho Michael H, Hatabu Hiroto, Putman Rachel K, Hunninghake Gary M
Division of Pulmonary and Critical Care Medicine.
Department of Radiology, and.
Am J Respir Crit Care Med. 2024 Dec 15;210(12):1453-1460. doi: 10.1164/rccm.202402-0313OC.
Some with interstitial lung abnormalities (ILA) are suspected to have interstitial lung disease (ILD), a subgroup with adverse outcomes. Rates of development and progression of suspected ILD and their effect on mortality are unknown. To determine rates of development, progression, and mortality in those with suspected ILD and assess effects of individual ILD and progression criteria. Participants from COPDGene (Genetic Epidemiology of Chronic Obstructive Pulmonary Disease) with ILA characterization and FVC at enrollment and 5-year follow-up were included. ILD was defined as ILA and fibrosis and/or FVC < 80% predicted. Prevalent ILD was assessed at enrollment and incident ILD and progression were assessed at 5-year follow-up. Computed tomography (CT) progression was assessed visually and FVC decline as relative change. Multivariable Cox regression tested associations between mortality and prevalent ILD, incident ILD, and progression groups. Of 9,588 participants at enrollment, 268 (2.8%; 51% of ILA) had prevalent ILD. Those with prevalent ILD had 51% mortality after median 10.6 years, which was higher than those with ILA without prevalent ILD (henceforth ILA) (33%; hazard ratio [HR], 2.0; < 0.001). The subgroup of prevalent ILD with only fibrosis criteria (FVC ≥ 80%) had worse mortality (58%) than ILA (HR, 2.2; < 0.001). A total of 98 participants with prevalent ILD completed 5-year follow-up: 33% had stable CT and relative FVC decline <10%, 6% had FVC decline ≥10% only, 39% had CT progression only, and 22% had both CT progression and FVC decline ≥10%. Mortality rates were 31%, 50%, 45%, and 45%, respectively; those with only CT progression had worse mortality than those with ILA (HR, 2.6; = 0.005). At 5-year follow-up, incident ILD occurred in 148/4,842 participants without prevalent ILD (5.5/1,000 person-years) and had worse mortality than ILA (HR, 2.4; < 0.001). Rates of mortality and progression are high among those with suspected ILD in COPDGene; fibrosis and radiologic progression are important predictors of mortality.
一些患有间质性肺异常(ILA)的患者被怀疑患有间质性肺疾病(ILD),这是一个具有不良预后的亚组。疑似ILD的发生和进展率及其对死亡率的影响尚不清楚。为了确定疑似ILD患者的发生、进展和死亡率,并评估个体ILD和进展标准的影响。纳入慢性阻塞性肺疾病基因研究(COPDGene,慢性阻塞性肺疾病的遗传流行病学)中在入组时和5年随访时有ILA特征及用力肺活量(FVC)数据的参与者。ILD被定义为ILA以及纤维化和/或FVC低于预测值的80%。在入组时评估现患ILD,在5年随访时评估新发ILD和进展情况。通过视觉评估计算机断层扫描(CT)进展情况,FVC下降以相对变化来衡量。多变量Cox回归分析了死亡率与现患ILD、新发ILD和进展组之间的关联。入组的9588名参与者中,268名(2.8%;占ILA的51%)患有现患ILD。患有现患ILD的患者在中位10.6年后的死亡率为51%,高于无现患ILD的ILA患者(此后简称ILA)(33%;风险比[HR],2.0;P<0.001)。仅符合纤维化标准(FVC≥80%)的现患ILD亚组的死亡率(58%)高于ILA(HR,2.2;P<0.001)。共有98名患有现患ILD的参与者完成了5年随访:33%的患者CT稳定且FVC相对下降<10%,6%的患者仅FVC下降≥10%,39%的患者仅CT进展,22%的患者CT进展且FVC下降≥10%。死亡率分别为31%、50%、45%和45%;仅CT进展的患者死亡率高于ILA患者(HR,2.6;P=0.005)。在5年随访时,4842名无现患ILD的参与者中有148名发生了新发ILD(5.5/1000人年),其死亡率高于ILA(HR,2.4;P<0.001)。在COPDGene研究中,疑似ILD患者的死亡率和进展率较高;纤维化和放射学进展是死亡率的重要预测因素。